Scribe Therapeutics Inc.
SCTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 3, 2026 |
Earnings History
Next report: Dec 2, 2026 · EPS est. $-0.42| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 2, 2026 | $-2.62 | $-3.62 | $1.9M | $3.1M |
News
ALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that management will participate in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Boston, MANov. 10, 20…
Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe's lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials A second presentation will reveal enhanced potency and specificity preclinical data for STX-1200, Scribe's gene editing program designed to lower lipoprotein(a) CEO to participate in the inaugural AHA Innovation Forum's sessions on entrepreneurship and AI in cardiovascular innovation ALAMEDA, Calif., Nov. 04, 20…
Ark Invest added to three existing positions on Monday, all of them down sharply from recent highs.
Scribe Therapeutics is initiated with a buy rating, targeting the in-vivo gene therapy market for cardiometabolic diseases with lead asset STX-1150. STX-1150 aims to provide durable, reversible PCSK9 silencing for cholesterol lowering, with preclinical data showing 52-68% LDL-C reduction for at least two years in primates. SCTX is funded into 2029, reducing near-term dilution risk, and holds strategic partnerships with Sanofi and Eli Lilly, offering potential milestone upside.
Scribe Therapeutics Inc. (NASDAQ: SCTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes Awarded more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance both STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry Completed upsized initial public offering, including …
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference Boston, MASept.
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that could reshape your portfolio heading into a volatile fall.